Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality control
Lukas‐Adrian Gurzeler, Marion Link, Yvonne Ibig, Isabel Schmidt, Olaf Galuba, Julian Schoenbett, Christelle Gasser-Didierlaurant, Christian N. Parker, Xiaohong Mao, Francis Bitsch, Markus Schirle, Philippe Couttet, Frederic Sigoillot, Jana Ziegelmüller, Anne‐Christine Uldry, Wojciech Teodorowicz, Niko Schmiedeberg, Oliver Mühlemann, Jürgen Reinhardt
Abstract
(Cell Reports 42, 113056; September 26, 2023) This manuscript is a joint publication by Novartis and an academic lab. Since the principal investigator of the academic lab (O.M.) was managing all contacts with the publisher from submission to acceptance of the paper, the publisher designated O.M. as the lead contact in the pre-proof version of the article. In the proofing process, the corresponding authors requested to list both O.M. and J.R. as lead contacts, but the publisher insisted on having only one lead contact. Since we expect that readers of this article will request mainly materials that belong to Novartis, O.M. and J.R. decided to designate J.R. as the new lead contact. Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality controlGurzeler et al.Cell ReportsAugust 30, 2023In BriefGurzeler et al. present two potent readthrough promoters, NVS1.1 and NVS2.1, that restore functional full-length proteins in cystic fibrosis and Hurler disease models. These compounds promote readthrough of premature termination codons by triggering eRF1 degradation by a ribosome-associated quality control pathway involving GCN1, RNF14, and RNF25. Full-Text PDF Open Access